Eli Lilly and Company finalized the sale of its biopharmaceutical production facility in Branchburg, New Jersey, to South Korea-based Celltrion. Celltrion announced the completion of the transfer on January 2, 2026.
Lilly executed the sale as part of its strategy to optimize its manufacturing footprint. The transaction helps Lilly manage supply chain risks while ensuring continued product supply.
The deal establishes Celltrion as a contract manufacturing organization (CMO) for Lilly. This arrangement secures a local U.S. production base for the Korean firm and shortens its timeline for acquiring a cGMP-compliant facility in the U.S.
No significant market reaction for Eli Lilly was noted in the immediate aftermath of the announcement.